Cancer Database Query Results

Scientific Papers found: Click to Expand⟱
5411- ASA,    Mechanistic Insights into a Classic Wonder Drug—Aspirin
- Review, Var, NA
*COX2↓, *COX1↓, *Inflam↓, *cardioP↑, Risk↓,
5410- ASA,    Low-Dose Aspirin and the Prevention of Colorectal Cancer in Inflammatory Bowel Disease: A Nationwide Cohort Study
- Study, CRC, NA
Risk↓, Dose↝, Risk↓,
5408- ASA,    An aspirin a day keeps cancer at bay
- Review, Var, NA
TumMeta↓, TXA2↓, *AntiAg↑, COX1↓,
5400- ASA,    Beyond COX-1: the effects of aspirin on platelet biology and potential mechanisms of chemoprevention
- Review, Nor, NA
Risk↓, *Inflam↓, *COX1↓, *AntiAg↑, *Half-Life↓, *BioAv↑,
5401- ASA,    Residual cyclooxygenase activity of aspirin-acetylated COX-2 forms 15R-prostaglandins that inhibit platelet aggregation
- Review, Nor, NA
*AntiAg↑, *COX1↓,
5399- ASA,    Effect of Aspirin on Cancer Incidence and Mortality in Older Adults
- Trial, Nor, NA
Risk↝, Risk↑, Risk∅, Risk↑, other↝,
5409- ASA,    Role of aspirin in cancer prevention
- Review, Var, NA
Imm↑, *Inflam↓, *AntiAg↑, *GutMicro↑, eff↑, TumMeta↓, angioG↓, Risk↓, Risk↓,
5402- ASA,    Aspirin prevents metastasis by limiting platelet TXA2 suppression of T cell immunity
- Review, Var, NA
COX1↓, TumMeta↓, *Half-Life↓, *COX2↓, *TXA2↓,
5404- ASA,    Low-Dose Aspirin and Prevention of Colorectal Cancer: Evidence From a Nationwide Registry-Based Cohort in Norway
- Study, CRC, NA
Risk↓, other↝, Dose↝, Risk↓, other↓, other↝, KRAS↓, other↓, other↓,
5405- ASA,    Exploring Aspirin’s Potential in Cancer Prevention: A Comprehensive Review of the Current Evidence
- Review, Var, NA
Risk↓, COX1↓, PGE2↓, Inflam↓, *AntiAg↓, PI3K↓, Akt↓, Risk↓,
5406- ASA,    Adjuvant aspirin therapy and colorectal cancer survival
- Trial, CRC, NA
Dose↝, OS∅,
5407- ASA,    Low-dose aspirin reduces the risk of colorectal cancer recurrence in patients with resected PI3K-altered localised disease, according to the ALASCCA trial.
- Trial, CRC, NA
Dose↝, Risk↓,
1304- ASA,    Aspirin Inhibits Colorectal Cancer via the TIGIT-BCL2-BAX pathway in T Cells
- in-vitro, CRC, NA - in-vivo, NA, NA
TumCP↓, Apoptosis↑, Bcl-2↓, BAX↑, IL10↓, TNF-β↓,
1028- ASA,    Aspirin Suppressed PD-L1 Expression through Suppressing KAT5 and Subsequently Inhibited PD-1 and PD-L1 Signaling to Attenuate OC Development
- vitro+vivo, Ovarian, NA
TumCP↓, TumW↓, PD-L1↓, Ki-67↓, H3K27ac∅, eff↑,
1096- ASA,    Aspirin inhibit platelet-induced epithelial-to-mesenchymal transition of circulating tumor cells (Review)
- Review, NA, NA
TumMeta↓, COX1↓, CTC↓,
1142- Ash,    Ashwagandha-Induced Programmed Cell Death in the Treatment of Breast Cancer
- Review, BC, MCF-7 - NA, BC, MDA-MB-231 - NA, Nor, HMEC
Apoptosis↑, ROS↑, DNAdam↑, OXPHOS↓, *ROS∅, Bcl-2↓, XIAP↓, survivin↓, DR5↑, IKKα↓, NF-kB↓, selectivity↑, *ROS∅, eff↓, Paraptosis↑,
5393- Ash,    Studies on oral bioavailability and first-pass metabolism of withaferin A in rats using LC-MS/MS and Q-TRAP
- in-vivo, Nor, NA
*BioAv↝, *other↝, *Half-Life↓,
5394- Ash,    Safety and pharmacokinetics of Withaferin-A in advanced stage high grade osteosarcoma: A phase I trial
- Trial, OS, NA
toxicity↝, hepatoP↓, BioAv↓, Apoptosis↑, ROS↑, TumCCA↑,
5395- Ash,    Withaferin A Targets Heat Shock Protein 90 in Pancreatic Cancer Cells
- vitro+vivo, PC, PANC1 - in-vitro, PC, MIA PaCa-2
TumCP↓, HSP90↓, Akt↓, CDK4↓, TumCG↓, Apoptosis↑, AntiCan↑,
5396- Ash,    Withania Somnifera (Ashwagandha) and Withaferin A: Potential in Integrative Oncology
- Review, Var, NA
selectivity↑, ROS↑, Apoptosis↑, ChemoSen↑, RadioS↑, NF-kB↓, ER-α36↓, P53↑, *ROS∅, γH2AX↑, DNAdam↑, MMP↓, XIAP↓, IAP1↓, survivin↓, SOD↓, Dose↝, IL6↓, TNF-α↓, COX2↓, p‑Akt↓, NOTCH1↓, FOXO↑, Casp↑, MMP2↓, CSCs↓, *ROS↓, *SOD2↑, chemoP↑, ChemoSen↑, RadioS↑,
5398- Ash,    Withaferin-A inhibits colorectal cancer growth and metastasis by targeting the HSP90/HIF-1α/EMT axis
- in-vitro, CRC, HCT116 - in-vitro, CRC, SW48
TumCG↓, TumCMig↓, TumCI↓, HSP90↓, Hif1a↓, EMT↓,
3673- Ash,    An overview on ashwagandha: a Rasayana (rejuvenator) of Ayurveda
- Review, NA, NA
*cognitive↑, *Inflam↓, *Strength↑, *VitC↑, *memory↑,
3675- Ash,    Ashwagandha (Withania somnifera) Reverses β-Amyloid1-42 Induced Toxicity in Human Neuronal Cells: Implications in HIV-Associated Neurocognitive Disorders (HAND)
*memory↑, *neuroP↑, *Aβ↓, *LDH↓, *PPARγ↑, *cognitive↑,
3676- Ash,    Effect of Withania somnifera (Ashwagandha) root extract on amelioration of oxidative stress and autoantibodies production in collagen-induced arthritic rats
- in-vivo, Arthritis, NA
*CRP↓, *ROS↓, *lipid-P↓, *GSTs↓, *GSH↑, *antiOx↑, *Inflam↓,
3668- Ash,    Withania somnifera reverses Alzheimer's disease pathology by enhancing low-density lipoprotein receptor-related protein in liver
- NA, AD, NA
*Aβ↓, *cognitive↑,
3669- Ash,    Withanamides in Withania somnifera fruit protect PC-12 cells from beta-amyloid responsible for Alzheimer's diseas
- in-vitro, AD, PC12
*lipid-P↓, *antiOx↑,
3670- Ash,    Neurodegenerative diseases and Withania somnifera (L.): An update
- Review, AD, NA - Review, Park, NA
*Apoptosis↓, *Inflam↓, *ROS↓, *neuroP↑,
3674- Ash,    Ashwagandha in brain disorders: A review of recent developments
- Review, NA, NA
*neuroP↑,
3685- Ash,    Withania somnifera as a Potential Anxiolytic and Anti-inflammatory Candidate Against Systemic Lipopolysaccharide-Induced Neuroinflammation
- in-vivo, NA, NA
*TNF-α↓, *IL1β↓, *IL6↓, *iNOS↓, *COX2↓, *NOX↓, *cognitive↑, *Inflam↓, *NF-kB↓,
3686- Ash,    Adaptogenic and Anxiolytic Effects of Ashwagandha Root Extract in Healthy Adults: A Double-blind, Randomized, Placebo-controlled Clinical Study
- Study, NA, NA
*Sleep↑,
3687- Ash,    Role of Withaferin A and Its Derivatives in the Management of Alzheimer’s Disease: Recent Trends and Future Perspectives
- Review, AD, NA
*Aβ↓, *tau↓, *HSPs↝, *antiOx↑, *ROS↓, *Inflam↓, *neuroP↑, *cognitive↑, *NF-kB↓, *HO-1↑, *memory↑, *AChE↓, *BChE↓, *ChAT↑, *Ach↑,
3688- Ash,    Withaferin A Suppresses Beta Amyloid in APP Expressing Cells: Studies for Tat and Cocaine Associated Neurological Dysfunctions
- NA, AD, SH-SY5Y
*Aβ↓, *neuroP↑,
3689- Ash,    Ashwagandha attenuates TNF-α- and LPS-induced NF-κB activation and CCL2 and CCL5 gene expression in NRK-52E cells
- in-vitro, NA, NRK52E
*RenoP↑, *NF-kB↓, *MCP1↓, *RANTES↓,
3671- Ash,    Withania somnifera showed neuroprotective effect and increase longevity in Drosophila Alzheimer’s disease model
- in-vivo, AD, NA
*OS↑, *BACE↓,
3672- Ash,    Critical review of the Withania somnifera (L.) Dunal: ethnobotany, pharmacological efficacy, and commercialization significance in Africa
- Review, NA, NA
*cardioP↑, *antiOx↑, *ROS↓, *neuroP↑, *Inflam↓, *Apoptosis↓,
3170- Ash,    Withaferin A protects against hyperuricemia induced kidney injury and its possible mechanisms
- in-vitro, Nor, NRK52E - in-vivo, NA, NA
*RenoP↑, *hepatoP↑, *creat↓, *BUN↓, *uricA↓, *Apoptosis↓, *α-SMA↓,
3169- Ash,    Withaferin A blocks formation of IFN-γ-induced metastatic cancer stem cells through inhibition of the CXCR4/CXCL12 pathway in the UP-LN1 carcinoma cell model
- in-vitro, GC, NA
CXCR4↓, CXCL12↓,
3179- Ash,    Withaferin A inhibits JAK/STAT3 signaling and induces apoptosis of human renal carcinoma Caki cells
- in-vitro, RCC, Caki-1
JAK↓, STAT3↓, Apoptosis↑,
3177- Ash,    Emerging Role of Hypoxia-Inducible Factors (HIFs) in Modulating Autophagy: Perspectives on Cancer Therapy
- Review, Var, NA
Hif1a↓, ROS↑, ER Stress↑,
3176- Ash,    Apoptosis is induced in leishmanial cells by a novel protein kinase inhibitor withaferin A and is facilitated by apoptotic topoisomerase I-DNA complex
- in-vitro, NA, NA
PKCδ↓, TOP1∅, ROS↑, GSH↓, DNAdam↑, MMP↓, Cyt‑c↑,
3175- Ash,  SFN,    Withaferin A and sulforaphane regulate breast cancer cell cycle progression through epigenetic mechanisms
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, MCF-7
DNMTs↓, HDAC↓, eff↑,
3174- Ash,    Withaferin A Acts as a Novel Regulator of Liver X Receptor-α in HCC
- in-vitro, HCC, HepG2 - in-vitro, HCC, Hep3B - in-vitro, HCC, HUH7
NF-kB↓, angioG↓, Inflam↓, TumCP↓, TumCMig↓, TumCI↓, Sp1/3/4↓, VEGF↓, angioG↓, uPA↓, PDGF↓, MCP1↓, ICAM-1↓, *NRF2↑, *hepatoP↑,
3173- Ash,    Nano-targeted induction of dual ferroptotic mechanisms eradicates high-risk neuroblastoma
- in-vitro, neuroblastoma, NA
GPx4↓, HO-1↑, lipid-P↑, Keap1↓, NRF2↑, Ferroptosis↑,
3172- Ash,    Implications of Withaferin A for the metastatic potential and drug resistance in hepatocellular carcinoma cells via Nrf2-mediated EMT and ferroptosis
- in-vitro, HCC, HepG2 - in-vitro, Nor, HL7702
Keap1↑, NRF2↓, EMT↓, TumCP↓, TumCI↓, selectivity↑, *toxicity↓, ROS↑, MDA↑, GSH↓, Ferroptosis↑,
3171- Ash,    Unlocking the epigenetic code: new insights into triple-negative breast cancer
- Review, BC, NA
DNMTs↓,
3178- Ash,    Withaferin A Inhibits Neutrophil Adhesion, Migration, and Respiratory Burst and Promotes Timely Neutrophil Apoptosis
- Review, Nor, NA
ITGB1↓,
2388- Ash,    Withaferin A decreases glycolytic reprogramming in breast cancer
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, MDA-MB-468 - in-vitro, BC, MCF-7 - in-vitro, BC, MDA-MB-453
GlucoseCon↓, lactateProd↓, ATP↓, Glycolysis↓, GLUT1↓, HK2↓, PKM2↓, cMyc↓, Warburg↓, cMyc↓,
3168- Ash,    Withaferin A targeting both cancer stem cells and metastatic cancer stem cells in the UP-LN1 carcinoma cell model
- in-vitro, Var, NA
CXCR4↓, STAT3↓, CSCs↓,
3154- Ash,    Pharmacokinetics and bioequivalence of Withania somnifera (Ashwagandha) extracts – A double blind, crossover study in healthy adults
BioAv↑, BioAv↓,
3155- Ash,    Overview of the anticancer activity of withaferin A, an active constituent of the Indian ginseng Withania somnifera
- Review, Var, NA
Half-Life↝, Inflam↓, antiOx↓, angioG↓, ROS↑, BAX↑, Bak↑, E6↓, E7↓, P53↑, Casp3↑, cl‑PARP↑, STAT3↓, eff↑, HSP90↓, TGF-β↓, TNF-α↓, EMT↑, mTOR↓, NOTCH1↓, p‑Akt↓, NF-kB↓, Dose↝,

Showing Research Papers: 851 to 900 of 5772
Prev Page 18 of 116 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 5772

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

antiOx↓, 1,   Ferroptosis↑, 2,   GPx4↓, 1,   GSH↓, 2,   HO-1↑, 1,   Keap1↓, 1,   Keap1↑, 1,   lipid-P↑, 1,   MDA↑, 1,   NRF2↓, 1,   NRF2↑, 1,   OXPHOS↓, 1,   ROS↑, 7,   SOD↓, 1,  

Mitochondria & Bioenergetics ⓘ

ATP↓, 1,   MMP↓, 2,   XIAP↓, 2,  

Core Metabolism/Glycolysis ⓘ

cMyc↓, 2,   GlucoseCon↓, 1,   Glycolysis↓, 1,   HK2↓, 1,   lactateProd↓, 1,   PKM2↓, 1,   Warburg↓, 1,  

Cell Death ⓘ

Akt↓, 2,   p‑Akt↓, 2,   Apoptosis↑, 6,   Bak↑, 1,   BAX↑, 2,   Bcl-2↓, 2,   Casp↑, 1,   Casp3↑, 1,   Cyt‑c↑, 1,   DR5↑, 1,   Ferroptosis↑, 2,   IAP1↓, 1,   Paraptosis↑, 1,   survivin↓, 2,  

Kinase & Signal Transduction ⓘ

Sp1/3/4↓, 1,  

Transcription & Epigenetics ⓘ

other↓, 3,   other↝, 3,  

Protein Folding & ER Stress ⓘ

ER Stress↑, 1,   HSP90↓, 3,  

DNA Damage & Repair ⓘ

DNAdam↑, 3,   DNMTs↓, 2,   P53↑, 2,   cl‑PARP↑, 1,   γH2AX↑, 1,  

Cell Cycle & Senescence ⓘ

CDK4↓, 1,   TumCCA↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

CSCs↓, 2,   EMT↓, 2,   EMT↑, 1,   FOXO↑, 1,   H3K27ac∅, 1,   HDAC↓, 1,   mTOR↓, 1,   NOTCH1↓, 2,   PI3K↓, 1,   STAT3↓, 3,   TOP1∅, 1,   TumCG↓, 2,  

Migration ⓘ

CXCL12↓, 1,   ER-α36↓, 1,   ITGB1↓, 1,   Ki-67↓, 1,   KRAS↓, 1,   MMP2↓, 1,   PDGF↓, 1,   PKCδ↓, 1,   TGF-β↓, 1,   TumCI↓, 3,   TumCMig↓, 2,   TumCP↓, 5,   TumMeta↓, 4,   uPA↓, 1,  

Angiogenesis & Vasculature ⓘ

angioG↓, 4,   Hif1a↓, 2,   TXA2↓, 1,   VEGF↓, 1,  

Barriers & Transport ⓘ

GLUT1↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX1↓, 4,   COX2↓, 1,   CXCR4↓, 2,   ICAM-1↓, 1,   IKKα↓, 1,   IL10↓, 1,   IL6↓, 1,   Imm↑, 1,   Inflam↓, 3,   JAK↓, 1,   MCP1↓, 1,   NF-kB↓, 4,   PD-L1↓, 1,   PGE2↓, 1,   TNF-α↓, 2,   TNF-β↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 2,   BioAv↑, 1,   ChemoSen↑, 2,   Dose↝, 6,   eff↓, 1,   eff↑, 4,   Half-Life↝, 1,   RadioS↑, 2,   selectivity↑, 3,  

Clinical Biomarkers ⓘ

CTC↓, 1,   E6↓, 1,   E7↓, 1,   IL6↓, 1,   Ki-67↓, 1,   KRAS↓, 1,   PD-L1↓, 1,  

Functional Outcomes ⓘ

AntiCan↑, 1,   chemoP↑, 1,   hepatoP↓, 1,   OS∅, 1,   Risk↓, 11,   Risk↑, 2,   Risk↝, 1,   Risk∅, 1,   toxicity↝, 1,   TumW↓, 1,  
Total Targets: 123

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 4,   GSH↑, 1,   GSTs↓, 1,   HO-1↑, 1,   lipid-P↓, 2,   NRF2↑, 1,   ROS↓, 5,   ROS∅, 3,   SOD2↑, 1,   uricA↓, 1,   VitC↑, 1,  

Core Metabolism/Glycolysis ⓘ

BUN↓, 1,   LDH↓, 1,   PPARγ↑, 1,  

Cell Death ⓘ

Apoptosis↓, 3,   iNOS↓, 1,  

Transcription & Epigenetics ⓘ

Ach↑, 1,   other↝, 1,  

Protein Folding & ER Stress ⓘ

HSPs↝, 1,  

Migration ⓘ

AntiAg↓, 1,   AntiAg↑, 4,   α-SMA↓, 1,  

Angiogenesis & Vasculature ⓘ

TXA2↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX1↓, 3,   COX2↓, 3,   CRP↓, 1,   IL1β↓, 1,   IL6↓, 1,   Inflam↓, 9,   MCP1↓, 1,   NF-kB↓, 3,   RANTES↓, 1,   TNF-α↓, 1,  

Cellular Microenvironment ⓘ

NOX↓, 1,  

Synaptic & Neurotransmission ⓘ

AChE↓, 1,   BChE↓, 1,   ChAT↑, 1,   tau↓, 1,  

Protein Aggregation ⓘ

Aβ↓, 4,   BACE↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↑, 1,   BioAv↝, 1,   Half-Life↓, 3,  

Clinical Biomarkers ⓘ

creat↓, 1,   CRP↓, 1,   GutMicro↑, 1,   IL6↓, 1,   LDH↓, 1,  

Functional Outcomes ⓘ

cardioP↑, 2,   cognitive↑, 5,   hepatoP↑, 2,   memory↑, 3,   neuroP↑, 6,   OS↑, 1,   RenoP↑, 2,   Sleep↑, 1,   Strength↑, 1,   toxicity↓, 1,  
Total Targets: 58

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page